




HLA EPİTOP UYUMU


Prof.Dr.MUSTAFA SOYÖZ


İZMİR KATİP ÇELEBİ ÜNİVERSİTESİ TIP FAKÜLTESİ

TIBBİ BİYOLOJİ AD.


Sunum Planı

- HLA epitopları/epletler
- Transplantasyonda HLA epitopları ve epletlerin önemi
- Retrospektif çalışmalarda HLA epitop/eplet eşleştirmesinin faydaları
- Prospektif HLA epitop/eplet eşleştirmesindeki fırsatlar
- Ulusal düzeyde neler yapabiliriz, bir yerden başlamalı mı?









T ve B Hücrelerin İşbirliği





epitope



Epitop







Recipient B*7

Donor 1	B*8
Donor 2	B*35
Donor 3	B*44

1 mismatch


1 mismatch

1 mismatch



		80	90
Recipient B*7		AQTDRESLRN LRGYYNQSEA	
Donor 1	B*8	T-----	
Donor 2	B*35	T--Y-----	
Donor 3	B*44	T--Y--N--T ALR-----	

HLA Antijenlerinin Kendilerine Özgü Epitop Kombinasyonu Var, Ama...




HLA antigen 1


HLA antigen 2

HLA antigen 3


HLA antigen 4



HLA sınıf I genleri için HLAMatchmaker v02'de mevcut olan HLA alellerinin ve bunlarla ilişkili epletlerin tam kütüphanesinin ağıları




HLA sınıf II genleri için HLAMatchmaker v02'de mevcut olan HLA alellerinin ve bunlarla ilişkili epletlerin tam kütüphanesinin ağıları




a

Class I
Alleles (n=206)

**b**

Class II
Alleles (n=155)






PRA 0%




PRA >0%


Highly Sensitized

cPRA




Epitope based cPRA






1. T cell clones



2. B cell clones







Algoritmalarla Risk Değerlendirmesi (DSA)






				<u>HLA Class I</u>	<u>HLA-DR</u>	<u>HLA-DQ</u>
	1	LOW RISK	 PIRCHE <i>HLAMatchmaker</i> As Algorithm for Selection LOW LOW  PIRCHE <i>HLA-EMMA</i> Empirical Mismatch Algorithm LOW LOW	→ 0% (0/14) → 5% (1/18)	0% (0/25) 0% (0/35)	0% (0/9) 8% (1/13)
	2	HIGH RISK	 PIRCHE <i>HLAMatchmaker</i> As Algorithm for Selection HIGH HIGH  PIRCHE <i>HLA-EMMA</i> Empirical Mismatch Algorithm HIGH HIGH	→ 20% (13/64) → 21% (14/66)	13% (6/45) 17% (7/41)	12% (9/73) 14% (10/73)
	3	LOWER RISK	 PIRCHE <i>HLAMatchmaker</i> As Algorithm for Selection LOW HIGH  PIRCHE <i>HLA-EMMA</i> Empirical Mismatch Algorithm HIGH LOW	→ 8% (1/10)	4% (1/23)	7% (1/14)
			 PIRCHE <i>HLA-EMMA</i> Empirical Mismatch Algorithm LOW HIGH  PIRCHE <i>HLA-EMMA</i> Empirical Mismatch Algorithm HIGH LOW	→ 6.3% (1/16)	8.3% (2/24)	0% (0/14)

n= 2787

dnDSA&greft sağkalımı





n= 2787
dnDSA








— 1 antigen mismatch, PIRCHE-II high
— 1 antigen mismatch, PIRCHE-II low
— 0 antigen mismatches


PIRCHE-II Skorlaması ve T-Hücre Aracılı Ret



PIRCHE-II Skorlaması ve T-Hücre Aracılı Ret







Nerden Başlamalı?

1

- Çalışma Grubu

2

- Yüksek çözünürlüklü HLA Tiplemesi
- Eplet/Epitop MM Algoritmaları
- Düşük ve Yüksek Risk Tanımlamaları


3

- Biopsi Skorları
- Klinik Veriler

İstatistiksel Analizler

Multidisipliner Bakış Açısı...





Özet

Moleküler uyumluluk immünolojik riski daha iyi tanımlar

Hasta/Donör moleküler uyumu; HLA Matchmaker, HLA-EMMA ve PIRCHE algoritmaları ile tahmin edilebilir

Moleküler uyumluluk mükemmel bir prognostik belirteçtir

Adaptif bağışıklık yanıtındaki T/B hücrelerinin işbirliği nedeniyle T hücre peptit uyumsuzluğunu ve B hücre epitop uyumsuzluğu ile birleştirip değerlendirmek daha ayrıntılı ve kesin risk tanımlanmasına olanak tanır

Ükümüzde bu alanda yapılacak çalışmalara ihtiyaç var...